Comparison of the Clinical Expression of Patients with Ankylosing Spondylitis from Europe and Latin America

Mariana, Benegas; Muñoz-Gomáriz, Elisa; Font, Pilar; Burgos‐Vargas, Rubén; Chaves, J. M.; Palleiro, Daniel; Cocco, José Maldonado; Gutiérrez, Miguel; Saénz, Ricardo; Steckmen, Ivan; Rillo, Oscar; Mulero, Juan; Sampaio-Barros, Percival D.; Barcelos, Anabela; Cruyssen, Bert Vander; Vázquez‐Mellado, Janitzia; Estévez, E. Collantes

doi:10.3899/jrheum.110687

Cited by 50 publications

(43 citation statements)

References 29 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Benegas et al [10] examined patients from National Registries, including 2356 patients from Europe and 1083 from Latin America. A lower prevalence of HLA-B27 was found in the Latino group (71%) compared to Europeans (83%).…”

Section: Discussionmentioning

confidence: 99%

“…Also seen in this study was slightly greater functional impairment (BASFI score 4.8 in Latin-American AS patients versus 4.3 in Europeans) and worse AS-related Quality of Life (ASQoL) (7 in Latin-Americans vs. 6 in Europeans). However, the authors did not regard these differences as being clinically relevant [10]. This also appears regarding the data from BASFI (4.3 vs. 4.8) and the ASQoL (6 vs. 7) [10].…”

Section: Discussionmentioning

confidence: 99%

“…There are no previous studies comparing objective, validated measures of disease severity of Black patients relative to White patients with AS. Likewise, the issue of AS severity in Latinos has not been examined comparatively except in one study that only examined national registries from Latin American and Europe [10]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups

et al. 2017

View full text Add to dashboard Cite

The purpose of this study is to compare disease severity in ankylosing spondylitis (AS) in three ethnic groups. We assessed 925 AS patients (57 Blacks, 805 Whites, 63 Latinos) enrolled in the longitudinal Prospective Study of Outcomes in AS (PSOAS) for functional impairment, disease activity, and radiographic severity. Comparisons of clinical characteristics and HLA-B27 frequency for each group were performed, in two multivariable regression models, we compared the baseline Bath Ankylosing Spondylitis Radiographic Index (BASRI) and modified Stokes Ankylosing Spondylitis Spine Score (mSASSS) by ethnicity, adjusting for covariates. Blacks had greater functional impairment (Bath Ankylosing Spondylitis Functional Index) (median 62.5 vs. 27.8 in Whites and 38.1 in Latinos; p < 0.0001); higher disease activity (Bath Ankylosing Spondylitis Disease Activity Index), (median 5.9 vs. 3.5 in Whites and 4.5 in Latinos; p < 0.0001), erythrocyte sedimentation rate (median 27.0 in Blacks vs. 10.0 in Whites and 17.0; p < 0.0001), and C-reactive protein levels (median 1.2 vs. 0.4 mg/dL in Whites and 0.9 in Latinos; p < 0.0001). Baseline BASRI and mSASSS were higher in Blacks (mean 9.5 and median 38.2, respectively) compared to Whites (7.3 and 6.4) and Latinos (7.3 and 8.1), (p = 0.004, 0.007), respectively, more significant as disease duration increased. HLA-B27 occurred in 62.5% of Blacks, 85.3% of Whites, and 86.7% of Latinos (p < 0.0001). On multivariable analysis, higher BASRI and mSASSS were associated with Black ethnicity, after adjusting for disease duration and gender as well as TNF inhibitor (TNFi) usage, smoking status, or education level. Blacks with AS have more severe disease compared to either Whites or Latinos.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Lo interesante es que alrededor del 80-95% de las personas caucasoides con EA presentan positividad para HLA B27, por lo que establecer una relación entre su presencia y el desarrollo de la enfermedad ha sido el objetivo de numerosas investigaciones. En otros grupos étnicos, la relación con el HLA-B27 no es tan estrecha 1,4,5 . De este modo, sabemos que la presencia de HLA-B27 no significa que una persona padezca o vaya a padecer EA, pero en el caso de existir determinados síntomas, variaciones en parámetros bioquímicos y ciertos signos radiológicos, existiría un indicador que puede contribuir al diagnóstico definitivo, e incluso que podría ser útil en el diagnóstico diferencial de otras patologías.…”

unclassified

Genética, HLA-B27 y espondilitis anquilosante: 40 años

Castro‐Santos¹,

Gutiérrez²,

Díaz‐Peña³

2014

Rev. méd. Chile

View full text Add to dashboard Cite

Genetics of ankylosing spondylitis Ankylosing spondylitis (AS) is a prototypical inflammatory disease of the locomotor system affecting axial skeleton. It is part of the general group of spondyloarthopathies (SpAEpidemiología L a espondilitis anquilosante (EA) es el prototipo de las enfermedades inflamatorias del aparato locomotor que afectan al esqueleto axial y que se engloban bajo el término de espondiloartropatías (SpA). La EA es una patología de etiología desconocida cuyas principales alteraciones se producen en las zonas de inserción de ligamentos y tendones en el hueso (entesis), en la membrana sinovial y en el cartílago articular. Se considera que afecta más frecuentemente a los varones (en una relación de 3:1 respecto de las mujeres) y aparece normalmente entre los 20-30 años de vida. La prevalencia de la EA varía según zona geográfica, etnia, factores genéticos y ambientales, persistiendo aún muchos factores que se desconocen 1 . La investigación de la EA ha dado un papel fundamental al antígeno de histocompatibilidad HLA-B27, molécula capaz de acoplar un péptido en su interior que permite la posterior activación del linfocito T, y por tanto, imprescindible para el reconocimiento de lo propio y lo ajeno por parte del sistema inmune. Las diferencias en la prevalencia de HLA-B27 explican la mayor parte de la variación en la prevalencia de la EA vista en todo el mundo 2,3 . Presentar en nuestro organismo este antígeno supone una probabilidad de 1-2% de padecer EA, aunque aumenta hasta el 10-20% si, además de ser B27-positivo, existe un familiar de primer grado que ya padece la enfermedad. Lo interesante es que alrededor del 80-95% de las personas caucasoides con EA presentan positividad para HLA B27, por lo que establecer una relación entre su presencia y el desarrollo de la enfermedad ha sido el objetivo de numerosas investigaciones. En otros grupos étnicos, la relación con el HLA-B27 no es tan estrecha 1,4,5 . De este modo, sabemos que la presencia de HLA-B27 no significa que una persona padezca o vaya a padecer EA, pero en el caso de existir determinados síntomas, variaciones en parámetros bioquímicos y ciertos signos radiológicos, existiría un indicador que puede contribuir al diagnóstico definitivo, e incluso que podría ser útil en el diagnóstico diferencial de otras patologías.

show abstract

“…There is a greater frequency of arthritis and enthesitis among SpA patients from Latin America (LA) compared with patients from Europe, and approximately 14% of LA patients were on a biological therapy regimen [11]. In Canada and Italy, the reported use anti-TNF in a cohort of patients with axial spondyloarthritis was 60% [12,13].…”

Section: Introductionmentioning

confidence: 99%

Infections with biological therapy: strategies for risk minimization in tropical and developing countries

Pérez-Díaz

Uribe-Pardo

Calixto

et al. 2016

J Infect Dev Ctries

View full text Add to dashboard Cite

In recent decades, biological therapy has enabled disease activity control and improved quality of life in patients with autoimmune diseases. These therapies that are involved in immune response modifications and change multiple immunological pathways induce an incremental risk for certain infectious diseases. Though there have been recent advances in risk assessment for biological therapy, there is a lack of data and recommendations for assessing risks in populations with high prevalence of infectious diseases, such as those located in tropical areas and developing countries. We performed a review on infections with biological therapy as well strategies for risk minimization in areas with a high prevalence of tropical diseases.

show abstract

Comparison of the Clinical Expression of Patients with Ankylosing Spondylitis from Europe and Latin America

Cited by 50 publications

References 29 publications

Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups

Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups

Genética, HLA-B27 y espondilitis anquilosante: 40 años

Infections with biological therapy: strategies for risk minimization in tropical and developing countries

Contact Info

Product

Resources

About